HC Surgical Specialists Limited (SGX: 1B1) FY2026 Financial Analysis
HC Surgical Specialists Limited (“HCSS” or the “Group”) released its unaudited results for the six months and full year ended 31 May 2026. The company operates a network of specialist clinics in Singapore, focusing on endoscopic procedures and general surgery. Below is a detailed analysis of the key financial metrics, performance drivers, and outlook based strictly on the published report.
Key Financial Metrics and Performance Summary
| Metric | 6M FY2026 (Dec 2025 – May 2026) |
6M FY2025 (Dec 2024 – May 2025) |
12M FY2026 | 12M FY2025 | YoY Change (12M) | QoQ Change (6M) |
|---|---|---|---|---|---|---|
| Revenue (S\$’000) | 9,602 | 9,166 | 19,380 | 19,108 | +1.4% | +4.8% |
| Profit After Tax (S\$’000) | 3,143 | 5,153 | 7,192 | 8,779 | -18.1% | -39.0% |
| EPS (cents) | 1.96 | 3.29 | 4.55 | 5.49 | -17.1% | -40.4% |
| Proposed/Declared Dividend (cents/share) | 0.90 (Interim) | 0.80 (Interim) | 2.08 (Interim + Final) | 1.50 (Interim + Final) | +38.7% | +12.5% |
| Net Asset Value per Share (S\$) | 13.63 | 13.66 | 13.63 | 13.66 | -0.2% | -0.2% |
Historical Performance Trends
- Revenue: The Group achieved a modest revenue growth of 1.4% YoY, primarily driven by the contribution from newly acquired subsidiaries.
- Profitability: Profit after tax and EPS both saw significant declines (-18.1% and -17.1% YoY respectively), with an even steeper drop in the latest half-year (-39% YoY for profit after tax, -40.4% for EPS).
- Dividends: Despite lower earnings, the Group raised its total dividend payout by 38.7% YoY to 2.08 cents per share, reflecting management’s confidence in cash flows and a commitment to shareholder returns.
- Net Asset Value: NAV per share remained stable.
Key Drivers, Exceptional Items, and Notable Events
- Expense Growth: Employee benefits expense increased due to higher headcount, regular salary increments, higher locum doctors’ fees, and new subsidiary acquisition.
- Fair Value Gains/Losses:
- Significant fair value gain on financial assets at FVTPL of S\$1.65 million, mainly from equity holdings in Medinex Limited, Aoxin Q & M Dental, and HSN Healthcare. This was offset by a fair value loss on derivative financial instruments (DFI) of S\$0.44 million due to re-measurement of forward purchase contracts.
- Acquisitions: The Group completed the acquisition of 51% of Chirurgia Pte. Ltd. in April 2026, contributing S\$405,000 to revenue and S\$148,000 to profit after tax post-acquisition. Goodwill of S\$1.23 million was recognized from this transaction.
- Divestments/Deemed Disposal: In FY2025, the Group recognized a loss of S\$0.21 million from the deemed disposal of its previous associate, MDS, which became a subsidiary.
- Related-Party Transactions: The Group entered into several related-party rental arrangements, all disclosed in the report.
- Dividend Policy: The Board has proposed a final dividend of 1.18 cents per share (subject to approval), on top of an interim dividend of 0.90 cents/share already paid, bringing the total annual dividend for FY2026 to 2.08 cents/share.
Cash Flow and Financial Position
- Operating cash flow remained strong and stable at S\$7.24 million for FY2026.
- Investing activities generated net cash inflow, mainly from dividends and disposals of financial assets, offset by new investments and plant/equipment purchases.
- Financing activities saw a net outflow due to higher dividend payments and repayment of lease and bank borrowings.
- Net cash and equivalents increased by S\$2.68 million to S\$7.78 million at year-end.
Corporate Actions and Subsequent Events
- The Group announced the acquisition of 51% of NYK Endoscopy and Digestive Centre Pte. Ltd. in June 2026 for S\$750,000, with an option to acquire the remaining 49% by November 2029. Goodwill of S\$750,000 is expected from this transaction.
- There were no share buybacks, dilutions, or placements during the period.
Risks, Outlook, and Chairman’s Statement
- The Group does not foresee immediate material impact from the adoption of AI technologies in healthcare, nor from macroeconomic or regulatory shifts, but remains vigilant.
- No significant legal disputes, natural disasters, or tax policy changes were reported.
Conclusion and Investment Recommendation
Overall Assessment: HC Surgical Specialists Limited delivered stable revenues and maintained a strong cash position, but profitability declined notably due to higher costs and the absence of exceptional gains seen in the prior year. Dividend payouts were raised, indicating confidence in future cash flows despite weaker earnings.
If You Are Currently Holding the Stock: The company’s fundamentals remain solid, with steady revenue and healthy operating cash flow. However, declining profits and rising costs are a concern. Investors may choose to hold the stock for dividend yield, but should monitor cost control and integration of new acquisitions closely.
If You Are Not Holding the Stock: The stock may offer an attractive dividend yield and some growth potential from new acquisitions. However, given the recent profit decline and rising expenses, it may be prudent to wait for clear signs of profit recovery or improved cost management before initiating a position.
Disclaimer: This analysis is based solely on the company’s published financial statements and does not constitute investment advice. Please conduct your own due diligence or consult a qualified adviser before making investment decisions.
HC Surgical Specialists Limited (SGX: 1B1) 2026财年财报分析（中文版）
HC Surgical Specialists Limited（简称“HCSS”或“集团”）公布了截至2026年5月31日止六个月及全年的未经审计财报。公司在新加坡经营专科诊所网络，专注于内窥镜手术及普通外科。以下基于报告内容进行详细分析。
主要财务指标及业绩总结
| 指标 | 2026年下半年 | 2025年下半年 | 2026财年全年 | 2025财年全年 | 同比变化 | 环比变化 |
|---|---|---|---|---|---|---|
| 收入 (千新元) | 9,602 | 9,166 | 19,380 | 19,108 | +1.4% | +4.8% |
| 税后利润 (千新元) | 3,143 | 5,153 | 7,192 | 8,779 | -18.1% | -39.0% |
| 每股收益EPS (分) | 1.96 | 3.29 | 4.55 | 5.49 | -17.1% | -40.4% |
| 分红（分/股） | 0.90（中期） | 0.80（中期） | 2.08（全年） | 1.50（全年） | +38.7% | +12.5% |
| 每股净资产NAV（新元） | 13.63 | 13.66 | 13.63 | 13.66 | -0.2% | -0.2% |
历史业绩趋势
- 收入： 2026财年收入同比增长1.4%，主要受益于新收购子公司贡献。
- 盈利能力： 税后利润及每股收益均大幅下滑，全年分别下跌18.1%和17.1%，下半年跌幅更甚。
- 分红： 尽管盈利下滑，全年总分红反而提升38.7%至2.08分/股，显示管理层对现金流充裕有信心。
- 净资产： 每股净资产基本持平。
业绩驱动、特殊项目与重要事件
- 费用增长： 员工薪酬费用增长，原因包括新子公司并表、常规调薪及临时医生费用增加。
- 公允价值变动：
- FVTPL金融资产公允价值收益达165万新元，主要来自Medinex、Aoxin Q&M Dental及HSN Healthcare等；但衍生金融工具公允价值损失44万新元，源于远期购股权重估。
- 收购： 2026年4月收购Chirurgia 51%股权，增加营收40.5万新元、净利润14.8万新元，形成商誉122.7万新元。
- 处置/视同处置： 2025财年视同处置MDS，录得损失21.2万新元。
- 关联交易： 多项关联方租赁交易均有详尽披露。
- 分红政策： 董事会建议派发2026财年末期股息1.18分/股（需股东大会批准），全年分红合计2.08分/股。
现金流与财务状况
- 经营现金流稳健，2026财年净流入724万新元。
- 投资活动净流入，主要来自金融资产分红及出售，部分对冲设备投入及新投资。
- 筹资活动净流出，主要用于分红、租赁及贷款还款。
- 年末现金及等价物提升至778万新元。
公司行动与后续事项
- 2026年6月收购NYK Endoscopy 51%股权，作价75万新元，预计产生75万新元商誉。
- 期间无回购、稀释或私募事项。
风险、展望及董事长声明
- 集团认为人工智能在医疗领域的短期影响有限，暂无重大宏观或政策风险。
- 报告期内无重大诉讼、自然灾害或税制变动。
结论与投资建议
总体评价： 公司营收稳定、现金流充沛，但盈利能力下滑明显，主因成本上升及缺乏前期的特殊收益。分红水平提升，显示管理层对公司现金流有信心。
已持股投资者建议： 公司基本面稳健，现金流良好，可继续持有获取分红，但需密切关注成本控制和新收购业务的整合效果。
未持股投资者建议： 股息回报具有吸引力，且新业务收购有增长潜力。但考虑到盈利下滑和成本压力，建议等待公司盈利回升或成本管控改善后再考虑买入。
免责声明： 本分析仅基于公司财报公开数据，不构成投资建议。请投资者务必自行调研或咨询专业顾问后作出决策。
